Artificial organs最新文献

{"title":"In Vitro Hemolytic Performance of the Novel Realheart Total Artificial Heart Versus SynCardia Total Artificial Heart With Human Blood.","authors":"Shaikh Faisal Zaman, Kerstin Jönsson Videsäter, Thomas Finocchiaro, Oliver Voigt, Ina Laura Perkins","doi":"10.1111/aor.70149","DOIUrl":"https://doi.org/10.1111/aor.70149","url":null,"abstract":"<p><strong>Background: </strong>The SynCardia Total Artificial Heart (TAH) is FDA-approved for bridge to transplantation and has been implanted in over 2000 patients. While hemolysis has been reported postimplantation, no published in vitro test data assess hemolysis or hematology. The Realheart TAH is a novel four-chamber pulsatile positive displacement TAH which mimics the natural heart's atrioventricular plane movement for physiological flow patterns and gentle blood handling. This study evaluates in vitro hemolytic performance of the SynCardia TAH against a newer prototype of the Realheart TAH, V11.2, using human blood.</p><p><strong>Methods: </strong>Hemolysis testing followed ASTM standards, F1830-97 and F1841-97 (2017) using pooled human whole blood diluted to a hematocrit of 30% ± 2%. The targeted flow and pressure head were 5 ± 0.25 L/min and 100 mmHg, respectively. Hematology parameters were analyzed, plasma free hemoglobin (pfHb) was measured, and milligram normalized index of hemolysis (mgNIH) and modified index of hemolysis (MIH) were calculated. Statistical analyses were performed.</p><p><strong>Results: </strong>Mean mgNIH (n = 6) were 18.11 ± 3.53 mg/100 L for V11.2 and 37.15 ± 12.42 mg/100 L for SynCardia (p < 0.05), a 2.05-fold increase in SynCardia TAH. MIH values were 1.69 ± 0.31 for V11.2 and 3.67 ± 1.29 for SynCardia (p < 0.05). Compared with the static control, SynCardia significantly reduced erythrocyte and increased platelet counts, effects not observed with the V11.2, whereas V11.2 significantly reduced leukocyte counts relative to the control.</p><p><strong>Conclusion: </strong>Realheart TAH V11.2 exhibited significantly lower hemolysis than SynCardia TAH in a modified systemic circulation test rig, indicating better hemocompatibility.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147727949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cold Atmospheric Plasma Therapy: An Innovative Approach to Treating Driveline Infections in Left Ventricular Assist Device Recipients.","authors":"Hebe Al Asadi, Martina Socha, Christiane Marko, Delphine Vanilla Cioffi, Roxana Moayedifar, Julia Riebandt, Daniel Zimpfer, Thomas Schlöglhofer","doi":"10.1111/aor.70135","DOIUrl":"https://doi.org/10.1111/aor.70135","url":null,"abstract":"<p><strong>Background: </strong>Driveline infections (DLIs) remain a present problem in left ventricular assist device (LVAD) patients, impacting quality of life and outcomes. The aim of this study was to evaluate the efficacy of usual care versus cold atmospheric plasma (CAP) for the treatment of DLI with three contemporary LVADs.</p><p><strong>Methods: </strong>This single center cohort study analyzed 78 LVAD outpatients, who developed a DLI during follow-up and were treated with standard care (n = 36), involving targeted antibiotics, silver-based dressings, surgical debridement, VAC-therapy, and in severe cases, pump replacement. The CAP (SteriPlas, Adtec Healthcare, UK) cohort received adjuvant CAP therapy (n = 42) 2-3× per week. The primary outcome was the efficiency of CAP treatment for DLI (wound healing) 12 months after start of intervention stratified by usual care versus CAP. Secondary outcomes included freedom from DLI-related hospital readmission, pump exchange and VAC implantation, as well as an analysis of CAP-specific parameters.</p><p><strong>Results: </strong>A total of 943 CAP sessions were performed with a median number of 17 (8; 36) sessions per patient. No side effects or pump malfunctions were observed during CAP therapy. Patients with more severe DLIs (higher DESTINE staging) required more CAP sessions to achieve healing (r = 0.42, p = 0.049). CAP versus usual care resulted in higher rates of wound healing (50% vs. 25%, p = 0.03) and less DLI-related hospital readmissions (19.0% vs. 54.5%, p < 0.001).</p><p><strong>Conclusion: </strong>Regardless of the type of bacteria, CAP provides a safe, non-contact therapy and easy treatment option for DLIs with significant improvement in LVAD patient outcomes and quality of life.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147727863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standardization of In Vitro Evaluation of Extracorporeal Life Support (ECLS) Devices for Research and Development.","authors":"Jutta Arens, Mirko Belliato, Lars Mikael Broman, Johanna C Clauser, Dirk W Donker, Roberto Lorusso, Maximilian Malfertheiner, Sasa Rajsic, Justyna Swol, Leen Vercaemst, Lisa Prahl Wittberg","doi":"10.1111/aor.70124","DOIUrl":"10.1111/aor.70124","url":null,"abstract":"<p><p>Extracorporeal life support (ECLS) technology has witnessed remarkable advancements during the last decades. However, further research and development of devices are required to increase, for example, performance-efficiency, hemocompatibility, and long-term stability. All novel devices, even in early research stages, must undergo rigorous testing and evaluation. Yet, these early evaluations are often conducted under nonstandardized conditions, resulting in data difficult to compare, interpret, or translate into clinical practice. Establishing well-defined, standardized in vitro testing protocols for all ECLS components and devices would represent a major step forward. Such protocols would improve methodological consistency and ensure reproducibility across research groups. This document, developed by an international group of ECLS experts from all disciplines in which such components are designed, developed, and applied, provides clear recommendations and standardized criteria for device testing according to international norms. Adoption of these criteria including the ways of reporting results will foster a unified approach among scientists, engineers, clinicians, and the medical device industry. Ultimately, this common framework will facilitate data interpretation, improve comparability of study results between different groups, making the review of studies more straightforward, as not every aspect of testing requires additional review and discussion, certainly favoring decision-making in the development and application of ECLS technologies.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147608055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ex Situ Abdominal Multivisceral Normothermic Machine Perfusion: A Research Protocol.","authors":"L Leonie van Leeuwen, Matthew L Holzner, Kimberly Feeney, Avery Fortier, Leona Kim-Schluger, Sander Florman, M Zeeshan Akhtar","doi":"10.1111/aor.70073","DOIUrl":"10.1111/aor.70073","url":null,"abstract":"<p><p>Machine perfusion has revolutionized organ preservation by enabling enhanced graft viability, real-time functional assessment, and targeted therapeutic interventions. However, isolated organ perfusion models may fail to replicate the physiological interplay between abdominal organs. Ex situ multivisceral perfusion offers a promising alternative by maintaining critical inter-organ relationships, potentially improving the viability of low-flow organs, better mimicking in situ physiology, and extending preservation times. This approach may be especially beneficial for multivisceral transplant recipients, who often present with complex clinical needs and limited options. A central challenge in developing multivisceral perfusion strategies is defining and measuring perfusion success. Key indicators include macroscopic graft appearance, hemodynamic and biochemical parameters during perfusion, and post-perfusion histological evaluation. Over the course of perfusion, characteristic changes such as bowel distension and loss of peristalsis may occur, especially during prolonged cases. Successful perfusion is marked by homogeneous graft perfusion, stable arterial flows at physiological pressures, minimal edema, effective lactate clearance, preserved perfusate pH, and sustained bile and urine production without excessive fluid losses. Here, we present a comprehensive, stepwise protocol for normothermic machine perfusion of porcine abdominal multivisceral grafts, designed to support preclinical development and translational efforts aimed at improving organ preservation and expanding the potential of multivisceral transplantation.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":"511-519"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145666954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valvular Complications Related to Microaxial Assist Device Use: A Case-Level Systematic Review.","authors":"George P Nolan, Magdalena C Hammond, Daler Rahimov, Chaitanya Karimanasseri, Nayeem Nasher, T Reese Macmillan, John W Entwistle, Keshava Rajagopal, Charles W Hoopes, Vakhtang Tchantchaleishvili","doi":"10.1111/aor.70056","DOIUrl":"10.1111/aor.70056","url":null,"abstract":"<p><strong>Background: </strong>Microaxial devices provide effective short-term hemodynamic support in patients with cardiogenic shock or during high-risk procedures. However, there is a paucity of data regarding device-associated valvular complications. We sought to pool existing data to understand its incidence, management, and outcomes.</p><p><strong>Methods: </strong>An electronic search was conducted in October 2024 to identify studies reporting microaxial device-associated valvular complications that did not resolve with device explantation. A total of 26 case reports and case series, representing 27 patients, were included. Patient-level data were extracted for analysis.</p><p><strong>Results: </strong>The median age was 50 years [IQR 34-65], and 78% (21/27) were male. The indications for microaxial support were cardiogenic shock (85.2%, 23/27), coronary bypass grafting (7.4%, 2/27), and high-risk percutaneous coronary intervention (7.4%, 2/27). The most commonly used devices were the Impella 5.0 (41%, 11/27) and Impella CP (22%, 6/27). Aortic regurgitation (AR) developed in 67% of patients (18/27). Mitral regurgitation (MR) developed in 33% (9/27) of patients, all of which were severe. The median duration of microaxial support was 10 [3-15] days. Overall, 74% (20/27) of patients underwent surgical management, 11% (3/27) underwent transcatheter treatment, and 15% (4/27) were managed nonoperatively. In-hospital/30-day mortality was 11% (3/27), including two deaths among patients with MR (22%) and one in a patient with AR (5.6%) with a pre-existing bioprosthetic aortic valve (p = 0.19). When considering the patients with only native valves and excluding the bioprosthetic aortic valve, mortality was significantly higher among MR patients compared to those with AR (MR: 22%; AR: 0%, p = 0.04). At a median follow-up of 183 [30-365] days, overall survival was 89% (24/27).</p><p><strong>Conclusion: </strong>AR was more common than MR; however, all MR cases were severe. MR may be associated with worse outcomes. Surgical management appears to be the most frequently employed strategy for valvular injury.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":"505-510"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145773366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electrical Stimulation of Denervated Muscle: A Narrative Review.","authors":"Linshan Chu, Jonathan C Jarvis, Brian J Andrews, James J FitzGerald","doi":"10.1111/aor.70076","DOIUrl":"10.1111/aor.70076","url":null,"abstract":"<p><strong>Background: </strong>Electrical stimulation is commonly employed for activation of paralyzed muscles in patients with neurological diseases and injuries. However, there are differences in the treatment approaches that are possible for upper motor neuron and lower motor neuron injuries.</p><p><strong>Methods: </strong>This narrative review synthesizes findings from preclinical studies and clinical reports published over the past decades. Key topics include stimulation parameters, muscle physiology under denervation, and outcomes of invasive and noninvasive interventions. The selection of sources was based on their relevance to denervated muscle stimulation in both experimental and therapeutic contexts.</p><p><strong>Results: </strong>This review critically examined the physiological and therapeutic differences between indirect and direct stimulation of muscles in upper motor neuron and lower motor neuron injury situations. It then focused on the much less well-established field of stimulation of denervated muscle, where there remains a pressing need for new clinical approaches. We explained the rationale for stimulating denervated muscles and the practical difficulties encountered in doing so, describing the use of both invasive and noninvasive devices in animal experiments and clinical trials. We then discussed related research using artificial reinnervation for denervated muscle stimulation and suggested directions for future exploration in this dynamic field.</p><p><strong>Conclusion: </strong>Stimulation of denervated muscle remains a promising but underdeveloped area. Electrical stimulation of denervated muscle can preserve muscle mass and potentially restore function. However, its clinical adoption has been limited by the exceptionally high stimulation thresholds required, which are approximately one thousand times higher than those for indirect muscle stimulation via intact lower motor neurons. These demands lead to significant challenges including discomfort, limited specificity due to the need for large electrodes, and the risk of tissue damage. Artificial reinnervation may offer a promising solution by enabling the use of conventional low-energy stimulation techniques. Additionally, the application of stimulation in free muscle transfers may further expand therapeutic options in this area.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":"493-504"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13125396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145843580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nuno Neves to Serve as an Associate Editor of Artificial Organs.","authors":"Vakhtang Tchantchaleishvili","doi":"10.1111/aor.70123","DOIUrl":"10.1111/aor.70123","url":null,"abstract":"","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":"491-492"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Driveline Infections Among Patients Supported With Left Ventricular Assist Devices: A Single Center Sixteen-Year Longitudinal Profile.","authors":"Anh Nguyen, Alexis Shafii, Gabriel Loor, Andrew Civitello, O Howard Frazier, Todd Rosengart, Kenneth Liao","doi":"10.1111/aor.70082","DOIUrl":"10.1111/aor.70082","url":null,"abstract":"<p><strong>Background: </strong>Left ventricular assist device (LVAD) driveline infections significantly impact patient outcomes. This study aimed to identify their risk factors.</p><p><strong>Methods: </strong>We analyzed LVAD data from our institutional Intermacs database (January 1, 2008-December 31, 2023), combining primary implants and pump exchanges. Patient characteristics were summarized as frequencies for categorical variables and median (IQR) for continuous variables. The nature of repeated infection events was handled by the Andersen-Gill method within a multivariable Cox proportional hazards model for cause-specific hazard of driveline infections, accounting for death and heart transplant as competing risks.</p><p><strong>Results: </strong>Our cohort included 1026 LVAD implants. Median patient age was 57.7, and 79.6% were male. Cumulative driveline infection rates at 1, 2, 3, 4, and 5 years were 11.9%, 19.6%, 29.3%, 38.9%, and 40.1%, respectively, with a median time to infection of 13.8 months. Severe diabetes (HbA1c ≥ 8) increased driveline infection risk by 52% (HR = 1.52, p = 0.031). Pulsatile-flow, fully magnetically levitated, and axial-flow LVADs had a 245%, 70%, and 44% higher risk of driveline infections compared to partial magnetically levitated LVADs (HR = 3.45, p = 0.003; HR = 1.70, p = 0.066; HR = 1.44, p = 0.087, respectively). Paradoxically, patients 40 or above had over 58% lower risk of driveline infections than those under 40 (HR < 0.42, p < 0.001). In addition, coronary artery disease was associated with 56% lower risk of driveline infections (HR = 0.44, p = 0.001).</p><p><strong>Conclusions: </strong>Driveline infections remain prevalent in LVAD patients, especially those with severe diabetes. The lower driveline infection risk in older patients, those with coronary artery disease, and partially magnetically levitated LVADs warrants further investigation.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":"572-579"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13125384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145803182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma Adsorption Perfusion (BR-350) Versus Open Albumin Dialysis (OPAL) for Hyperbilirubinemia in Hepatic Failure in Cirrhotic Patients.","authors":"Justa Friebus-Kardash, Alica Ochs, Amina Louzi, Andreas Kribben, Bartosz Tyczynski, Jassin Rashidi-Alavijeh, Andreas Schütte, Hartmut H Schmidt, Amos Zeller","doi":"10.1111/aor.70090","DOIUrl":"10.1111/aor.70090","url":null,"abstract":"<p><strong>Background: </strong>In the last decades, various extracorporeal liver support systems were developed for hepatic failure with hyperbilirubinemia with the aim to clear the blood from protein-bound toxic molecules. Open albumin dialysis (OPAL) is a complex and expensive system that requires addition of human albumin. Plasma adsorption perfusion (PAP) using the anion exchange resin adsorber, BR-350, is an alternative liver support method that does not need additional blood products and is more cost-effective and less time-consuming.</p><p><strong>Methods: </strong>At the University Hospital Essen, PAP using BR-350 was performed in a cohort of 9 patients with a mean of 6 sessions per patient. In a retrospective analysis, we compared the detoxification ability of PAP with that of the OPAL system conducted among 24 patients and with standard medical treatment (SMT) including hemodialysis that was performed among 24 patients. In addition, the technical effectiveness of a single session of PAP with BR-350 was compared with OPAL among 12 patients who were treated with both methods in a crossover design.</p><p><strong>Results: </strong>The first single session (30.7.3 ± 13.5 mg/dL to 25.8 ± 13.4 mg/dL, p = 0.02) and the complete therapy (30.7 ± 13.5 mg/dL to 16.2 ± 6.3 mg/dL, p = 0.004) with PAP using BR-350 resulted in a statistically significant decrease of bilirubin concentrations. The median relative reduction of bilirubin achieved at the end of liver support treatment was comparable between PAP and OPAL (47% vs. 40%, p = 0.29). PAP was associated with a higher bilirubin reduction than the SMT plus dialysis (47% vs. -30%, p = 0.0001). The crossover comparison between the single session of PAP using BR-350 and OPAL revealed similar mean relative reduction rates of bilirubin (11% vs. 10%, p = 0.81). The single session of OPAL was associated with a more pronounced decrease of alkaline phosphatase, gamma-glutamyltransferase, hemoglobin, platelets, and leucocytes compared to PAP.</p><p><strong>Conclusions: </strong>Both studied methods had comparable efficacy in reducing bilirubin in our studied patients in contrast to the retrospective control group. Since other substrates may also be relevant in treating liver failure, more studies are required. Patients with concomitant renal failure benefit from OPAL, whereas PAP might be more eligible for patients with a high risk of bleeding.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":"610-624"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13125386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145942404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnetic Field-Driven Electrogenic Scaffold Enhances the Nerve Regeneration.","authors":"Yue Hui, Chang Sun, Qi Yang, Guoyin Liu, Tao Yuan, Peng He, Xiabing Qin","doi":"10.1111/aor.70065","DOIUrl":"10.1111/aor.70065","url":null,"abstract":"<p><strong>Background: </strong>Neural conduits (NGCs) are widely used for peripheral nerve regeneration but have shown limited therapeutic effects. Electrical stimulation combined with NGCs is becoming a new treatment paradigm. Conventional electrical stimulation approaches for nerve regeneration are typically hindered by inconvenience, infection, and may cause secondary damage.</p><p><strong>Methods: </strong>This study developed a non-contact electrical stimulation platform using a magnetic field-coupled polycaprolactone/conductive polymer poly(3,4-ethylenedioxythiophene)/black phosphorus nerve conduit. This composite nerve conduit exhibited excellent electrical properties and biocompatibility. When placed in an external rotating magnetic field, it was able to transmit pulsed currents into the targeted sites due to electromagnetic induction.</p><p><strong>Results: </strong>The regeneration levels achieved with the magnetic field-driven nerve conduit were comparable to those of autologous transplantation. Immunofluorescence and histochemistry results demonstrated that this magnetic field-driven nerve conduit enhances axonal regeneration, neovascularization, and inflammation regulation.</p><p><strong>Conclusion: </strong>This work opens a new avenue for low-invasive and high-security bioelectronic therapy for long-segment peripheral nerve defects, with potential applications in various tissue regeneration engineering.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":"520-529"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145646990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}